Research Article Details
| Article ID: | A53136 |
| PMID: | 10905124 |
| Source: | Ital Heart J |
| Title: | [Ischemic cardiopathy: risk factors and their biological role]. |
| Abstract: | Atherosclerosis is a slowly progressive process, involving the intima and media of large and medium sized arteries and leading to the formation of focal lesions (plaques), containing lipid and fibrous tissue. A classification of atherosclerotic lesions includes: isolated foam cells, fatty streaks, preatheroma, atheroma, and fibroatheroma. Fibroatheroma is an unstable lesion, which might be complicated by intraplaque hemorrhage, rupture and overimposed thrombosis, leading to ischemia. This is the main mechanism responsible for myocardial infarction, stroke, and intermittent claudication. A widely accepted hypothesis for the pathogenesis of atherosclerosis is the response to the injury hypothesis. Endothelial damage or dysfunction is associated with increased arterial wall permeability to plasma constituents and with adhesion of platelets and monocytes, releasing growth factors and chemoattractant molecules. Several factors, in particular hyperlipidemia, arterial hypertension, diabetes mellitus, produce endothelial damage, which is followed by other cellular reactions involved in the atherosclerotic process. Since long time it has been reported that atherosclerosis has some features of the inflammatory processes. The inflammatory response in the arterial system is to some extent different from that occurring in other tissues and organs, such as the liver, kidney, lung or joints. The measurement of metabolic markers of coronary risk (cholesterolemia, homocysteinemia, glycosylated hemoglobin) is useful to estimate the global coronary risk in the individual patient. The demonstration of atherosclerotic plaques by noninvasive ultrasounds provides a sensitive marker of early arterial disease, allowing an objective evaluation of the response of the arterial system to different treatments. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I16 | 6713 | Cerebrovascular disease | An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. http://en.wikipedia.org/wiki/Cerebrovascular_disease, http://www.ncbi.nlm.nih.gov/books/NBK378/ | disease of anatomical entity/ cardiovascular system disease/ vascular disease/cerebrovascular disease | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |